GlassScriptPhysician profile
Kelly Wilkinson
NPI 1639481856
$79,227.75
in general payments reported to CMS, 2019-2025
81 companies · $3,150 in 2025
The $3,150 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,409 · 2021: $5,374 · 2022: $8,112 · 2023: $23K · 2024: $15K · 2025: $3,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $6,853 · Consulting Fee: $6,400 · Travel and Lodging: $2,065 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,650.00 |
| Food and Beverage | $6,853.06 |
| Consulting Fee | $6,400.00 |
| Travel and Lodging | $2,065.13 |
| Education | $243.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46,413.79 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Tesaro, INC. | $21,727.80 | 2019 | |
| Incyte Corporation | $907.97 | 2019-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $904.59 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $800.79 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Springworks Therapeutics, INC. | $543.27 | 2024-2025 | Ogsiveo |
| Astellas Pharma US INC | $511.08 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Pfizer INC. | $427.52 | 2019-2025 | |
| Celgene Corporation | $415.85 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $412.51 | 2019-2025 | |
| Gilead Sciences, INC. | $371.48 | 2023-2025 | Trodelvy |
| Exelixis INC. | $357.53 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $349.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $305.59 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Amgen INC. | $300.78 | 2019-2022 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $285.93 | 2019-2025 | Iclusig, Alunbrig |
| Merck Sharp & Dohme LLC | $281.54 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $279.16 | 2020-2023 | Tukysa, Adcetris |
| Rigel Pharmaceuticals, INC. | $226.72 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Abbvie INC. | $216.48 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $200.65 | 2021-2025 | Xpovio |
| Sobi, INC | $141.36 | 2025 | |
| Genentech USA, INC. | $133.89 | 2019-2024 | Venclexta, Tecentriq, Polivy |
| Adc Therapeutics America, INC. | $119.26 | 2021-2025 | |
| Immunocore Limited | $117.33 | 2023-2025 | Kimmtrak |
| Recordati_rare_diseases_inc. | $110.80 | 2023-2025 | Sylvant, Panhematin |
| Emd Serono, INC. | $105.89 | 2021-2024 | Bavencio |
| Lilly USA, LLC | $102.70 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Lucid Diagnostics INC. | $102.56 | 2022 | |
| Stemline Therapeutics INC. | $85.12 | 2024-2025 | Orserdu |
| Morphosys, US INC. | $80.78 | 2021-2023 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $78.73 | 2019-2025 | Lynozyfic |
| Sanofi-Aventis U.S. LLC | $77.99 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.62 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $75.93 | 2019-2024 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.33 | 2020-2025 | Gilotrif |
| Dova Pharmaceuticals | $64.60 | 2021 | |
| Eisai INC. | $64.43 | 2019-2022 | |
| Daiichi Sankyo INC. | $63.75 | 2024 | Injectafer, Enhertu, Vanflyta |
| Beigene USA, INC. | $60.15 | 2021-2024 | Brukinsa |
| Adaptive Biotechnologies Corporation | $59.64 | 2024-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $58.21 | 2025 | |
| Genmab U.S., INC. | $54.06 | 2023-2025 | Epkinly, Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $52.30 | 2023 | Imbruvica, Epkinly |
| Verastem, INC. | $51.84 | 2019 | |
| Pharmacosmos Therapeutics INC. | $51.62 | 2021-2024 | Cosela |
| Coherus Oncology, INC. | $47.84 | 2024 | |
| Dendreon Pharmaceuticals LLC | $47.74 | 2019-2020 | |
| Kyowa Kirin, INC. | $47.20 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $45.70 | 2021-2023 | Ultomiris |
| Array Biopharma INC | $41.99 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Sanofi US Services INC. | $40.23 | 2025 | |
| Beone Medicines USA, INC. | $39.98 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $39.88 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $39.35 | 2024-2025 | |
| Legend Biotech USA INC. | $38.93 | 2024-2025 | Carvykti |
| Secura Bio, INC. | $37.38 | 2020-2022 | |
| Puma Biotechnology, INC. | $34.35 | 2023-2024 | |
| Blueprint Medicines Corporation | $31.99 | 2021-2024 | Ayvakit |
| Alnylam Pharmaceuticals INC. | $30.01 | 2022-2025 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $25.75 | 2019-2020 | |
| Syndax Pharmaceuticals, INC. | $25.15 | 2025 | |
| Novo Nordisk INC | $23.13 | 2024 | Esperoct |
| Geron Corporation | $23.01 | 2025 | Rytelo |
| Invivyd INC | $21.59 | 2025 | Pemgarda |
| Taiho Oncology, INC. | $19.96 | 2024 | |
| Acrotech Biopharma INC. | $18.22 | 2021 | |
| Kite Pharma, INC. | $18.19 | 2025 | Yescarta |
| Epizyme, INC. | $18.01 | 2021 | |
| Axsome Therapeutics, INC. | $16.75 | 2025 | Symbravo |
| Acceleron Pharma, INC. | $16.66 | 2021 | |
| Clovis Oncology, INC. | $15.78 | 2019 | |
| Deciphera Pharmaceuticals INC. | $15.69 | 2022 | |
| Becton, Dickinson and Company | $15.21 | 2022 | |
| Servier Pharmaceuticals LLC | $13.79 | 2021 | |
| Caris Mpi, INC. | $13.72 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $13.54 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $13.36 | 2020 | |
| G1 Therapeutics, INC. | $12.90 | 2022 | |
| Tersera Therapeutics LLC | $12.11 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.